| Mechanism of action | It acts by binding to sterols in the fungus cell membrane, producing a change in membrane permeability that allows leakage of intracellular components from the cell. |
| Standard dosage | Cryptococcal meningitis: Amphotericin B: 0.7 to 1 mg/kg/day IV or lipid formulation amphotericin B 4–6 mg/kg IV daily plus flucytosine 100 mg/kg/day orally in 4 divided doses for 4 to 6 weeks (induction), followed by fluconazole 400 mg/day orally for 8 weeks (consolidation), then fluconazole 200 mg/day orally for 6 to 12 months (maintenance). |
| Major side effects | Hypotension, cardiac dysrhythmia, normochromic, normocytic anemia, agranulocytosis, nephrotoxicity, hypokalemia, thrombophlebitis. Dosages of 1.5 mg/kg/day can cause cardiac arrest. |
| Major drug interactions | Concomitant use of nephrotoxic medications or those with cardiac effects should be avoided or closely monitored. |
| Special points | It is the drug of choice for most CNS mycoses despite limited CNS penetration. Liposomal preparations have better penetration and lower toxicity. In select cases can be given intrathecally. |